Xylo

Executive Summary

Xylo is a San Francisco-based biotechnology company founded in 2021 that is pioneering next-generation neurotherapeutics aimed at rewiring neural circuits and restoring brain function. By leveraging computational drug discovery and medicinal chemistry, the company develops small molecules designed to enhance neuroplasticity for the treatment of psychiatric and neurological disorders. Xylo's mission is to address critical unmet patient needs through mechanism-based therapies. As a private company in the psychedelics category, Xylo operates in a competitive landscape but differentiates itself with a focus on non-hallucinogenic, plasticity-enhancing compounds. The company has not disclosed funding, valuation, or pipeline details, indicating an early-stage profile. Its approach combines AI-driven design with traditional medicinal chemistry, potentially accelerating the development of novel treatments for conditions such as depression, anxiety, and neurodegenerative diseases. The lack of public milestones suggests Xylo is focused on preclinical research and drug discovery, with future catalysts likely centered around financing, research collaborations, or entry into clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Series A funding announcement60% success
• Q2 2027Lead candidate IND filing35% success
• Q3 2026Research partnership with academic institution50% success